Cephalon Inc. v. Sun Pharma Global FZE
1:13-cv-02096
Overview
Parties
Defendant
Sun Pharma Global FZE Operating Company
Represented By
8 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Cephalon Inc. Operating Company
Represented By
5 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Sun Pharmaceutical Industries Inc. Operating Company
Represented By
1 Attorneys ListedPhillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Sun Pharmaceutical Industries Ltd. Operating Company
Represented By
2 Attorneys ListedPhillips, Goldman, McLaughlin & Hall, P.A.
Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street
Phillips, McLaughlin & Hall, P.A.
Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8445524
Solid forms of bendamustine hydrochloride
|
Filed: 2011-11-22
Issued: 2013-05-21
|
Active (5.0 yrs remaining)
Expires: 2031-11-22
|
|
|
US8436190
Bendamustine pharmaceutical compositions
|
Filed: 2006-01-12
Issued: 2013-05-07
|
Active (3.9 yrs remaining)
+1748d PTA
Expires: 2030-10-26
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term — No obviousness-type double patenting noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings